Vulvovaginal candidiasis is the most prevalent vaginal infection worldwide. Considering the violence of the symptoms that some patients report, the tendency to relapse or of resistance to the azole therapy, and the success reported by some studies in the treatment with boric acid of the vaginal infection with various pathogens, we conducted a prospective study in which we used vaginal boric acid for Candida species infection. The aim of our study was to evaluate the effectiveness and tolerability of boric acid in the treatment of vaginal infection with Candida species. Analysing the data from the satisfaction questionnaire completed by the patients who reached the end of the study showed that our investigational product has a good and very good effectiveness in sterilizing the infection (71%), being considered by patients to be easily administered (67.7%), the safety of the product being perceived as good and very good by 93.6% of them.